GlassScriptPhysician profile
Jonathan M Tackett
NPI 1922369974
$2,769.76
in general payments reported to CMS, 2019-2025
28 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $269 · 2021: $336 · 2022: $333 · 2023: $676 · 2024: $620 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $726.28 | 2019-2025 | |
| Abbvie INC. | $309.57 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $217.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $203.60 | 2019-2023 | |
| Novo Nordisk INC | $193.91 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $130.73 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.54 | 2019-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $103.58 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $98.25 | 2021-2025 | |
| Lilly USA, LLC | $91.96 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $80.02 | 2021 | |
| Abbott Laboratories | $68.93 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $56.24 | 2020-2025 | Evenity |
| Merck Sharp & Dohme LLC | $55.80 | 2019-2020 | |
| Dexcom, INC. | $35.87 | 2024-2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $34.81 | 2023 | Watchman Access System |
| Idorsia Pharmaceuticals US INC | $32.54 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $31.00 | 2022-2023 | Injectafer |
| Exact Sciences Corporation | $30.89 | 2023 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $26.16 | 2024 | Tremfya |
| Grifols USA, LLC | $18.41 | 2024 | Prolastin-C Liquid |
| Nestle Healthcare Nutrition INC. | $17.60 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.79 | 2023 | Lifevest |
| Sunovion Pharmaceuticals INC. | $15.84 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.82 | 2025 | Caplyta |
| Mylan Specialty L.P. | $15.27 | 2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $14.39 | 2023 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Tackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.